Terns Pharmaceuticals, Inc.
TERN
Rankning i aktier
#3575
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the... Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Aktiekurs
$52.95
Senast synkroniserad: 2026-05-15
Marknadsvärde
$4.77B
Förändring (1 dag)
0.00%
Förändring (1 år)
514.27%
Land
US
Handel Terns Pharmaceuticals, Inc. (TERN)
Kategori
Healthcare
Antal utestående aktier för Terns Pharmaceuticals, Inc. (TERN)
Antal utestående aktier per December 2025: 93.17M
Enligt de senaste finansiella rapporterna och aktiekursen för Terns Pharmaceuticals, Inc. är det aktuella antalet utestående aktier 93.17M. I slutet av December 2023 hade företaget 71.26M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Terns Pharmaceuticals, Inc. (TERN) från 2018 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 93.17M | 17.18% |
| 2024 | 79.51M | 11.57% |
| 2023 | 71.26M | 97.76% |
| 2022 | 36.03M | 42.60% |
| 2021 | 25.27M | 0.57% |
| 2020 | 25.13M | 0.11% |
| 2019 | 25.10M | 4.69% |
| 2018 | 23.97M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 172.52% |
US
|
|
| 396.00M | 325.05% |
US
|
|
| 478.91M | 414.04% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -33.25% |
NL
|
